Below are current clinical trials.6 studies in Cardiovascular Surgery
(open studies only).
Filter this list of studies by location, status and more.
The goal of ths study is to determine the effectiveness of adding topical tranexamic acid (TXA) to our standard practice of care for patients undergoing redo or complex cardiac procedures. The study will use a control group for comparision.
Jacksonville, Fla., Rochester, Minn.
The purpose of this study is to evaluate the effectiveness of Vacuum-assisted dressings for treating patients who have open chest wounds by comparing the time-to-closure of such wounds to traditional wound care management.
The primary goal of this project is to describe the clinical and physiologic characteristics of Spontaneous Coronary Artery Dissections (SCAD) in order to increase awareness, understanding, treatment and prevention of a potentially fatal cardiovascular event.
This study will be a retrospective and prospective review of medical course and current health of men and women with SCAD.
Subjects for this study will have been diagnosed with a bulge or aneurysm in their abdominal aorta, which is the blood vessel in the abdomen (belly) that supplies blood to most of the lower body including major organs and the legs.
The purpose of this study is to gather safety and effectiveness of the Zenith t-Branch and customized physician-specified stent-graft with a combination of fenestrations and/or branches to repair the aneurysm.
The Zenith t-Branch and physician-specified fenestrated and branched endovascular graft is a tubular graft made of polyester fabric sewn to stainless steel stents that keep the graft open. As an aneurysm expands, the walls become weak and may rupture, causing a major loss of blood with a high risk of death and other serious complications. To avoid this risk the aneurysm will be repaired by putting a graft in place of the aneurysm. The graft will be inserted through arteries in the leg (called endovascular repair). This procedure uses catheters that go inside the blood vessel to place a stent graft above and below the aneurysm.
The upper portion of the graft includes 1 to 5 small holes (fenestrations) or cuffs (side branches) that allow the graft to be located above the renal arteries without blocking blood flow to them. These small holes or branches are the investigational part of this research study. This is needed when there is not enough healthy aorta below the renal arteries. At least one artery may also be treated with an alignment stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches. The Zenith t-Branch and physician-specified fenestrated and branched endovascular graft will be referred to as the Zenith Fenestrated-Branched System.
The specific aim of this study is to determine best practice in management of cardiac surgical patients with post- cardiopulmonary bypass (CBP)coagulopathy and bleeding. The aim is to compare outcomes in patients who receive acute normovolemic hemodilution (ANH) blood to control patients with post-CPB factor mediated coagulopathy and clinically significant microvascular bleeding who have did not receive ANH.
La Crosse, Wis., Eau Claire, Wis., Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.
Clopidogrel is an anti-platelet medication approved by the U.S. Federal Drug Administration (FDA) for use in patients who undergo Percutaneous Coronary Intervention (PCI) with coronary stent implantation. Anti-platelet medications work to prevent blood clots from forming. Some studies have suggested that patients who have a certain genetic liver enzyme abnormality (known as cytochrome P450 2C19 [CYP2C19] *2 or *3 allele) may have a reduced ability to activate clopidogrel, and therefore may have a lowered response to clopidogrel. It is thought that perhaps people who have a coronary stent procedure may have this genetic liver enzyme abnormality. There is a research genetic test available to determine whether or not someone has this genetic liver enzyme abnormality. Ticagrelor, is a newer anti-platelet drug that is not dependent on the CYP2C19 liver enzyme for its activation and hence in poor clopidogrel metabolizers, alternative drugs like Ticagrelor have been recommended for use as an anti-platelet agent after PCI. The purpose of this study is to determine if genetic testing can identify the best anti-platelet therapy, for patients who undergo a coronary stent placement and do not activate clopidogrel very well.
Oct. 06, 2016
- U.S. News & World Report. U.S. News Best Hospitals 2014-15. http://health.usnews.com/best-hospitals/rankings. Accessed Dec. 29, 2014.
- Tordsen BW. Surgical Information Recording System. Jan. 27, 2015.
- Find award-winning hospitals near you. American Heart Association. http://hospitalmaps.heart.org/AHAMAP/map/qimap.jsp. Accessed Jan. 27, 2015.
- Mayo Clinic Children's Center becomes first accredited pediatric heart failure institute in Minnesota and fourth in the nation. PressReleaseHeadlines.com. http://pressreleaseheadlines.com/mayo-clinic-childrens-center-accredited-pediatric-heart-failure-institute-minnesota-fourth-nation-174647. Accessed Jan. 27, 2015.
- Centers of Excellence. Extracorporeal Life Support Organization. http://www.elso.org/Excellence/CentersofExcellence.aspx. Accessed Jan. 27, 2015.
- Doctors name America's top residency programs. U.S. News & World Report. http://health.usnews.com/health-news/top-doctors/articles/2014/02/20/doctors-name-americas-top-residency-programs. Accessed Jan. 27, 2015.